Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results

Наслов

Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results

Идентификатор

/unibl/sci/idNaucniRad:25129

Тип

Датум

Библиографски цитат

J. Smolen, J. Choe, N. Prodanović, J. Niebrizidovski, I. Staikov, E. Dokoupilova, A. Baranauskaite, R. Iatsishin, M. Mekić, V. Poravska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, I. Lee, I. Rho, Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results, RHEUMATOLOGY, pp. 10 - 10, 2017

Почетна страница

10

Крајња страница

10

Је дио

Листа аутора

Position: 13153 (34 views)